David Mannino, MD

Mannino, Anzueto and Christenson conclude the panel with thoughts on developing biologics for COPD, and increased interest in the field after ensifentrine and dupilumab.

Ahead of the anticipated FDA decision in September, an expert panel reviews the promising data and unique role dupilumab may have in COPD.

In this HCPLive Special Report, experts review ensifentrine's role as a novel maintenance therapy for COPD.